Evidence map›Paper›PMID 40851321›Full record

GuidelineInternational journal of rheumatic diseases2025

2024 Update of Chinese Guidelines for Management of Hyperuricemia and Gout Part II: Recommendations for Patients With Common Comorbidities.

Changgui Li, Mingshu Sun, Zhen Liu, Detian Li, Changqian Wang, Zibin Tian, Yuxiang Dai, Zhe Feng, Chengfu Xu, Dongbao Zhao and 21 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in International journal of rheumatic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Changgui LiDepartment of Endocrinology, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, China.
Mingshu SunDepartment of Rheumatology, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, China.
Zhen LiuDepartment of Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Detian LiDepartment of Nephrology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Changqian WangDepartment of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Zibin TianDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Yuxiang DaiDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhe FengDepartment of Nephrology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Chengfu XuDepartment of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0002-6172-1253
Dongbao ZhaoDepartment of Rheumatology, The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital), Shanghai, China.
Feng WeiDepartment of Endocrinology, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, Neimonggu, China.
Bo BanDepartment of Endocrinology, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.ORCID https://orcid.org/0000-0002-3950-1422
Chao XieDepartment of Endocrinology and Metabolism, Peking University Third Hospital, Beijing, China.
Zhenmei AnDepartment of Metabolism, West China Hospital, Sichuan University, Chengdu, China.
Jia LiuDepartment of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0009-0000-0429-5748
Zhuo LiDepartment of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin, China.
Yuwei HeDepartment of Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Xinde LiDepartment of Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Fei YanDepartment of Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.ORCID https://orcid.org/0000-0002-3381-1489
Lin HanDepartment of Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Lidan MaDepartment of Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Xiaoyu ChengDepartment of Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Tian LiuDepartment of Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Xufei LuoResearch Unit of Evidence-Based Evaluation and Guidelines, Chinese Academy of Medical Sciences (2021RU017), School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu, China.
Lingling CuiDepartment of Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Ying GongDepartment of Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Can WangDepartment of Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Yaolong ChenResearch Unit of Evidence-Based Evaluation and Guidelines, Chinese Academy of Medical Sciences (2021RU017), School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu, China.ORCID https://orcid.org/0000-0002-9841-5233
Zhaohui LyuDepartment of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Ronald M L YipTung Wah Group of Hospitals Integrated Diagnostic and Medical Centre, Kwong Wah Hospital, Kowloon, Hong Kong, China.
Jiajun ZhaoDepartment of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.ORCID https://orcid.org/0000-0003-3267-9292

Funding

National Key Research and Development Program of China 2022YFC2503300National Key Research and Development Program of China 2022YFE0107600Projects of International Cooperation and Exchange NSFC 82220108015
6 · The paper itself

Abstract

objectiveThe aim of this updated guideline is to provide comprehensive recommendations for the management of gout in patients with common comorbidities, such as chronic kidney disease (CKD), cardiovascular disease (CVD), diabetes, osteoarthritis (OA), and gastrointestinal disorders.

methodsThis guideline was developed by a multidisciplinary expert panel consisting of specialists in endocrinology, rheumatology, nephrology, cardiology, gastroenterology, and methodology. The development process adhered to standard methodologies, including PICO (population, intervention, comparator, and outcomes) question deconstruction, systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) for evidence and recommendation evaluation, Delphi voting, and expert consensus.

resultsThe guideline presents 26 evidence-based recommendations addressing seven clinical questions for patients with hyperuricemia and gout in the context of comorbidities. Key recommendations include the maintenance of strict serum urate targets, particularly for patients with CKD stage ≥ 3, chronic gouty arthritis, and OA, in order to prevent disease progression. In patients with CVD or diabetes, intra-articular triamcinolone is preferred over systemic glucocorticoids. Prioritized anti-inflammatory treatments for patients with CKD, gastrointestinal diseases, and OA are recommended. The guideline also introduces emerging therapies, such as interleukin-1 inhibitors and selective urate transport inhibitors, as potential treatment options for refractory cases.

conclusionThe update offers a comprehensive, patient-centered approach to managing gout, particularly in individuals with associated comorbidities. Multidisciplinary collaboration and emerging new treatments and evidence ensure the optimization of the recommendations.

Indexed as

GoutGout SuppressantsHyperuricemiaCardiovascular DiseasesChinaComorbidityConsensusEvidence-Based MedicineHumansRenal Insufficiency, ChronicGout Suppressantscomorbiditygoutguidelinehyperuricemiamanagement

Identifiers

PMID40851321
PMCPMC12375887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.